Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10637/15202

EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old


Vista previa

Ver/Abrir:
 EAACI_Agache_et_al_Allergy_2022.pdf
907,89 kB
Adobe PDF
Título : EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old
Autor : Agache, Ioana
Akdis, Cezmi A.
Akdis, Mubeccel
Brockow, Knut
Chivato Pérez, Tomás
Eiwegger, Thomas
Eyerich, Kilian
Giménez-Arnau, Ana
Gutermuth, Jan
Guttman-Yassky, Emma
Maurer, Marcus
Ogg, Graham
Ong, Peck Y.
O’Mahony, Liam
Schwarze, Jürgen
Warner, Amena
Werfel, Thomas
Palomares, Oscar
Jutel, Marek
Giacco, Stefano del
Materias: Chronic spontaneous urticariaGRADEGuidelinesOmalizumab
Editorial : Wiley
Citación : Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old. Allergy. 2022;77:17– 38. https://doi.org/10.1111/all.15030
Resumen : Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H1R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.
URI : http://hdl.handle.net/10637/15202
Derechos: http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
ISSN : 1398-9995
Fecha de publicación : 2022
Centro : Universidad San Pablo-CEU
Aparece en las colecciones: Medicina





Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.